Related Experiment Video
Updated: Aug 11, 2026
08:17
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research
Published on: August 15, 2019
High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy
Thomas H Brannagan1, Armin Alaedini, Douglas E Gladstone
1Weill Medical College of Cornell University, Department of Neurology and Neuroscience, Peripheral Neuropathy Center, 635 Madison Avenue, Suite 400, New York, New York 10022, USA. THB2006@med.cornell.edu
Muscle & Nerve
|February 28, 2006
Summary
High-dose cyclophosphamide offers a potential new treatment for multifocal motor neuropathy (MMN) patients unresponsive to standard therapies. This approach may lead to sustained improvement and reduced reliance on other medications like IVIg.
Area of Science:
- Neurology
- Immunology
Background:
- Multifocal motor neuropathy (MMN) is a rare autoimmune disorder affecting peripheral nerves.
- Current treatments like intravenous immune globulin (IVIg) offer limited sustained benefit.
Observation:
- A patient with refractory MMN was treated with high-dose cyclophosphamide (50 mg/kg for 4 days) without stem cell rescue.
- The patient discontinued IVIg after successful treatment.
Findings:
- Significant improvement in muscle strength was observed 6 months post-treatment.
- The patient regained the ability to write, indicating functional recovery.
Implications:
- High-dose cyclophosphamide presents a promising therapeutic option for MMN patients resistant to conventional treatments.
- This approach may offer a more durable remission and improved quality of life for MMN patients.